Aelin Therapeutics · Company in Belgium Tech

Overview

Belgian biotechnology spin-off developing therapeutics through targeted protein aggregation. [1]

11 Dec 2017
Series AVenture / equity1 sourceEUR 27M
Reported amount EUR 27,000,000
Founder-supplied company announcement reproduced by university names December 11, 2017 and €27m Series A; VIB report corroborates amount and syndicate.
Corpus Christi College The Letter 97: Joost Schymkowitz on Aelin Therapeutics corpus.cam.ac.uk
Deal record
InvestorsLSPPMVNovartis Venture FundBoehringer Ingelheim Venture FundFund+
9 Jul 2020
Grant1 sourceEUR 2.3M
Reported amount EUR 2,300,000
Investor repost of company release dated July 9 announces €2.3m research grant.
Aelin Therapeutics awarded €2.3 million VLAIO research grant fundplus.be
Deal record
ParticipantsVLAIO

Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.

Status

KU Leuven Research & Development states that Aelin Therapeutics went into liquidation in 2023. The source gives a year only; no exact liquidation date is asserted.[4]

Something wrong or missing? Send an update. Fixed within 24 hours.